Ebix, Inc. (EBIX) Touches $84.65 High on Feb, 15; Vascular Biogenics Limited Ord (VBLT) Shorts Decreased By 19.49%

February 15, 2018 - By Peter Erickson

Vascular Biogenics Limited Ord (NASDAQ:VBLT) had a decrease of 19.49% in short interest. VBLT’s SI was 643,900 shares in February as released by FINRA. Its down 19.49% from 799,800 shares previously. With 623,000 avg volume, 1 days are for Vascular Biogenics Limited Ord (NASDAQ:VBLT)’s short sellers to cover VBLT’s short positions. The SI to Vascular Biogenics Limited Ord’s float is 7.74%. The stock decreased 1.18% or $0.076 during the last trading session, reaching $6.349. About 59,697 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has risen 78.91% since February 15, 2017 and is uptrending. It has outperformed by 62.21% the S&P500.

The stock of Ebix, Inc. (NASDAQ:EBIX) reached all time high today, Feb, 15 and still has $87.19 target or 3.00% above today’s $84.65 share price. This indicates more upside for the $2.66 billion company. This technical setup was reported by Barchart.com. If the $87.19 PT is reached, the company will be worth $79.89M more. The stock increased 0.95% or $0.8 during the last trading session, reaching $84.65. About 41,022 shares traded. Ebix, Inc. (NASDAQ:EBIX) has risen 21.95% since February 15, 2017 and is uptrending. It has outperformed by 5.25% the S&P500.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $188.72 million. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Among 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vascular Biogenics had 13 analyst reports since August 24, 2015 according to SRatingsIntel. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) earned “Buy” rating by H.C. Wainwright on Tuesday, June 28. The stock has “Overweight” rating by Piper Jaffray on Monday, November 9. As per Tuesday, October 3, the company rating was maintained by H.C. Wainwright. On Tuesday, August 15 the stock rating was maintained by H.C. Wainwright with “Buy”. Roth Capital maintained it with “Buy” rating and $13 target in Monday, August 24 report. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. The firm has “Mkt Outperform” rating by JMP Securities given on Monday, September 21. The firm earned “Buy” rating on Monday, September 21 by Chardan Capital Markets. The firm has “Buy” rating given on Tuesday, March 28 by H.C. Wainwright. As per Tuesday, November 7, the company rating was maintained by H.C. Wainwright.

Among 2 analysts covering Ebix (NASDAQ:EBIX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ebix had 4 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Buy” rating by William Blair on Thursday, September 28. On Tuesday, August 11 the stock rating was upgraded by Zacks to “Hold”. Craig Hallum maintained the stock with “Buy” rating in Thursday, November 9 report.

Investors sentiment increased to 1.23 in 2017 Q3. Its up 0.14, from 1.09 in 2017Q2. It increased, as 23 investors sold Ebix, Inc. shares while 42 reduced holdings. 27 funds opened positions while 53 raised stakes. 19.27 million shares or 1.10% less from 19.48 million shares in 2017Q2 were reported. 14,658 are held by Jane Street Gp Ltd Co. Piedmont Advsrs Llc owns 18,740 shares. Renaissance Group Incorporated Ltd Co has invested 0.01% in Ebix, Inc. (NASDAQ:EBIX). Alliancebernstein Ltd Partnership holds 0% or 36,900 shares. Us Bancshares De holds 0% in Ebix, Inc. (NASDAQ:EBIX) or 2,991 shares. Texas Permanent School Fund has invested 0.01% in Ebix, Inc. (NASDAQ:EBIX). 803,182 are held by First Trust Advsr L P. Dimensional Fund L P holds 575,704 shares. Solaris Asset Mgmt Llc stated it has 4,305 shares. Jpmorgan Chase stated it has 0% of its portfolio in Ebix, Inc. (NASDAQ:EBIX). Ahl Prns Llp reported 0.1% of its portfolio in Ebix, Inc. (NASDAQ:EBIX). Metropolitan Life reported 16,965 shares. Prudential Finance Inc reported 0% of its portfolio in Ebix, Inc. (NASDAQ:EBIX). Pnc Fin Ser Group Inc Inc has 253 shares for 0% of their portfolio. Fmr Lc invested in 4.70M shares or 0.04% of the stock.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>